Oncology Research Editorial Office

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.078461 - 19 January 2026

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.078460 - 19 January 2026

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.078459 - 19 January 2026

Abstract This article has no abstract. More >

Yang Wu^1,#,*, Dong Xu^1,#, Run Shi¹, Mingwei Zhan², Shaohui Xu³, Xin Wang⁴, Jianpeng Zhang⁵, Zhaokai Zhou⁶, Weizhuo Wang⁷, Yongjie Wang⁸, Minglun Li⁹, Zihao Xu^10,*, Kaifeng Su^11,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.073265 - 19 January 2026

Abstract Prostate cancer (PCa) remains a major cause of cancer-related mortality in men, largely due to therapy resistance and metastatic progression. Increasing evidence highlights the tumor microenvironment (TME), particularly cancer-associated fibroblasts (CAFs), as a critical determinant of disease behavior. CAFs constitute a heterogeneous population originating from fibroblasts, mesenchymal stem cells, endothelial cells, epithelial cells undergoing epithelial–mesenchymal transition (EMT), and adipose tissue. Through dynamic crosstalk with tumor, immune, endothelial, and adipocyte compartments, CAFs orchestrate oncogenic processes including tumor proliferation, invasion, immune evasion, extracellular matrix remodeling, angiogenesis, and metabolic reprogramming. This review comprehensively summarizes the cellular origins, phenotypic More >

Xinyang Li^1,2,3,#, Luyuan Ma^1,2,3,#, Chuan Shen^1,2,3, Ruolan Gu^1,2,3, Shilong Dong^1,2,3, Mingjie Liu^1,2,3, Ying Xiao^1,2,3, Wenpeng Liu^1,2,3, Yuexia Liu^1,2,3, Caiyan Zhao^1,2,3,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.073179 - 19 January 2026

Abstract Background: Hepatocellular carcinoma (HCC) is an aggressive and lethal malignancy. Metabolic reprogramming dynamically remodels the tumor microenvironment (TME) and drives HCC progression. This study investigated the mechanism through which metabolic reprogramming remodels the TME in HCC. Methods: HCC patient transcriptome data were subjected to bioinformatics analysis to identify differentially expressed genes and immune infiltration status. Immunohistochemical analysis was performed to determine the correlation between succinate dehydrogenase complex subunit A (SDHA) expression and M2 macrophage infiltration. SDHA-knockdown or SDHA-overexpressing HCC cells were used for in vitro experiments, including co-culturing, flow cytometry, and enzyme-linked immunosorbent assay. Western blotting… More >

Huan Zhang^1,#, Zhangwendi Xu^1,#, Yien Xu^1,#, Mao Li², Lingrui Liu¹, Caiyun He^1,*, Wenhuan Zhong^1,*, Jiliang Qiu^1,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.073079 - 19 January 2026

Abstract Objective: Ring finger protein 145 (RNF145), an E3 ubiquitin ligase, is significantly upregulated in hepatocellular carcinoma (HCC). However, its role in HCC remains unknown. The study aimed to investigate the functions and underlying mechanisms of RNF145 in HCC. Methods: The role of RNF145 in HCC was investigated using data from The Cancer Genome Atlas (TCGA) and in vitro experimental assays. Its oncogenic functions were assessed using the transwell migration assay and the wound-healing assay. The molecular mechanism was explored through protein immunoprecipitation and western blot analyses. Data from public databases were analyzed to correlate RNF145 expression… More >

Ke Liu^1,2,3,#, Xia Xue^1,2,3,#, Haiming Qin^4,5,#, Jiaying Zhu^6,#, Meng Jin^1,6, Die Dai⁶, Youcai Tang¹, Ihtisham Bukhari¹, Hangfan Liu¹, Chunjing Qiu¹, Feifei Ren¹, Pengyuan Zheng^1,2,3, Yang Mi^1,2,3,*, Weihua Chen^6,7,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.072661 - 19 January 2026

Abstract Background: The gut microbiome has emerged as a critical modulator of cancer immunotherapy response. However, the mechanisms by which gut-associated metabolites influence checkpoint blockade efficacy in prostate cancer (PC) remain not fully explored. The study aimed to explore how gut metabolites regulate death-ligand 1 (PD-L1) blockade via exosomes and boost immune checkpoint inhibitors (ICIs) in PC. Methods: We recruited 70 PC patients to set up into five subgroups. The integrated multi-omics analysis was performed. In parallel, we validated the function of gut microbiome-associated metabolites on PD-L1 production and immunotherapy treatment efficacy in PC cell lines… More >

Yuerou Feng, Panpan Tong, Shuwen Fu, Xiaofan Lu, Liquan Zheng, Jielan Lai^*, Renchun Lai^*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.072563 - 19 January 2026

Abstract Background: The efficacy of standard 5-fluorouracil (5-FU) chemotherapy for colorectal cancer is limited by drug resistance and adverse effects, prompting research into esketamine, a potent ketamine variant with analgesic, antidepressant, and recently discovered anti-tumor properties, to determine if it can enhance 5-FU’s chemosensitivity. This study investigates whether esketamine synergizes with 5-FU to enhance therapeutic efficacy in colorectal adenocarcinoma cell models. Methods: We performed functional assays to evaluate proliferation (CCK-8), migration (wound healing), invasion (Transwell), and apoptosis (flow cytometry) in colorectal adenocarcinoma cell lines treated with 5-FU alone or in combination with esketamine. Transcriptomic profiling was… More >

Xiaoyu Zhang^1,#, RenFei Zong^1,#, Yan Sun¹, Nan Chen², Kunyao Zhu¹, Hang Tong¹, Tinghao Li¹, Junlong Zhu¹, Zijia Qin¹, Linfeng Wu¹, Aimin Wang¹, Weiyang He^1,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.072084 - 19 January 2026

Abstract Objective: While cisplatin-based chemotherapy is pivotal for advanced bladder cancer, acquired resistance remains a major obstacle. This study investigates key molecular drivers of this resistance and potential reversal strategies. Methods: We established GC (Gemcitabine and Cisplatin)-resistant T24-R and UC3-R cell lines from T24 and UM-UC-3 (UC3) cells. Transcriptomic and proteomic analyses identified differentially expressed molecules. Apoptosis and cell viability were assessed by flow cytometry and CCK-8 (Cell Counting Kit-8) assays, while RT-qPCR (Reverse Transcription Quantitative Polymerase Chain Reaction) and Western blot analyzed gene and protein expression. Immunofluorescence evaluated FAK (Focal Adhesion Kinase) phosphorylation, and a… More >

Jiayu Zou^1,2,3, Yajie Lu³, Jiaqi Li³, Zhaokai Zhou^4,5, Fu Peng³, Pu Qiu^2,*, Hailin Tang⁶, Cheng Peng^1,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.071940 - 19 January 2026

Abstract Lung cancer is the most common but fatal malignant tumor worldwide. Patients with lung cancer experienced a relatively low 5-year overall survival rate, and issues such as metastasis and drug resistance remain prominent challenges in its clinical management. Neddylation, a novel type of post-translational modification, was overactivated in lung cancer and was closely associated with its occurrence, development, metastasis, and drug resistance. This review systematically summarizes the biological process of neddylation and deeply explores the latest research progress on how neddylation affects lung cancer cell proliferation, metastasis, and drug resistance mechanisms, with a focus on More >